Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2014
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
December 30, 2014

Nxt2b extends loan to Oasmia

Regulatory
December 30, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory
December 30, 2014

Oasmia receives a new MSEK 20 bank loan

Non Regulatory
December 18, 2014

Oasmia’s Chairman of the Board buys shares

Non Regulatory
December 17, 2014

Oasmia change to Mid Cap segment at Nasdaq Stockholm

Non Regulatory
December 12, 2014

Final result of Oasmia’s rights issue

Non Regulatory
December 10, 2014

Preliminary result of Oasmia’s rights issue

Regulatory
December 4, 2014

Prospectus addendum regarding Oasmia Pharmaceutical’s rights issue is now available

Non Regulatory
December 4, 2014

Interim report for the period May – October 2014

Regulatory
November 17, 2014

Prospectus, including new financial information, regarding Oasmia Pharmaceutical’s rights issue is now available

Regulatory
November 11, 2014

Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of approximately SEK 176 million

Non Regulatory
October 21, 2014

Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study

Non Regulatory
October 1, 2014

Communiqué from Oasmia’s Annual General Meeting 2014

Non Regulatory
September 30, 2014

Oasmia receives a new MSEK 40 bank loan

Non Regulatory
September 12, 2014

Oasmia considers secondary listing on NASDAQ USA

Regulatory
September 5, 2014

Interim report for the period May – July 2014

Non Regulatory
September 1, 2014

Correction of notice regarding notice of Annual General Meeting

Non Regulatory
September 1, 2014

Anders Blom new Executive Vice President in Oasmia

Non Regulatory
September 1, 2014

Notice convening the Annual General Meeting of Oasmia Pharmaceutical AB

Non Regulatory
August 21, 2014

The Oasmia Pharmaceutiacal Annual Report is now published

Regulatory
July 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory
July 3, 2014

Oasmia successfully completes private placement of SEK 50 million

Non Regulatory
July 2, 2014

Oasmia announces launch of private placement of new shares

Non Regulatory
June 25, 2014

Oasmia signs agreement for patented technology XR-17

Non Regulatory
June 24, 2014

Oasmia extends its production agreement with Baxter

Non Regulatory
June 16, 2014

Oasmia’s Lead Human Product Paclical® Successfully Meets Primary Objective in Pivotal Phase III Clinical Study

Non Regulatory
June 5, 2014

Year-end report for the fiscal year May 2013 – April 2014

Non Regulatory
June 2, 2014

Oasmia’s Lead Product Paccal Vet®-CA1 Presented at the ACVIM Forum in Nashville on June 4

Non Regulatory
May 15, 2014

Oasmia recruits a new CFO

Non Regulatory
May 14, 2014

Oasmia’s production facility approved in the EU

Regulatory
March 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Regulatory
March 31, 2014

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory
March 25, 2014

Oasmia receives a new MSEK 40 bank loan

Non Regulatory
March 7, 2014

Oasmia successfully completes private placement of approximately SEK 72 million

Non Regulatory
March 6, 2014

Oasmia announces launch of private placement of new shares

Non Regulatory
March 6, 2014

Interim report for the period May 2013 – January 2014

Non Regulatory
February 28, 2014

Oasmia Receives FDA Conditional Approval For Its Lead Product Paccal Vet®-CA1

Non Regulatory
January 21, 2014

Oasmia’s Chief Financial Officer Weine Nejdemo retires

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com